Non-small cell lung cancer
- Description
- Available tests: Fluorescence in situ hybridisation analysis of FFPE tissue sections for: ALK t(2p23;) rearrangement; ROS1 t(6q22;) rearrangement; MET (7q31) copy number/ratio; RET t(10q11;) rearrangement
- Clinical details
- The determination of ALK status in patients with lung cancer is critical in the identification of patients eligible for ALK inhibitor therapy. Patients with ROS1 rearrangement have also been shown to be sensitive to the ALK inhibitor crizotininb, MET amplification may contribute to acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI's), and may be a target for MET inhibitors. Patients showing rearrangement of RET have been shown to benefit from treatment with RET tyrosine kinase inhibitors.
- Synonyms
- ALK, ROS1, MET, RET, crizotininb, Xalkori, lung cancer, non-small cell lung cancer, adenocarcinoma, NSCLC
- Testing site
- Synnovis : Genomics : Guy's Hospital
- Laboratory
- Cancer Genetics
- Sample type and volume required
- FFPE tissue sections - 3-4µm sections on unstained Apes slides with appropriate IHC/H&E slide for correlation
- Turnaround time
- Current service turnaround times: Urgent 2-7 calendar days; Non-urgent 5-10 calendar days; National targets: Urgent samples 95% reported within 14 days; Non-urgent 95% reprted within 21 days
- Contacts
Cancer Genetics at Guy’s Hospital
Phone: 020 7188 1716
Email: synnovis.seglh-ods@nhs.net
Genetics Department
Guy’s Hospital
Great Maze Pond
London SE1 9RT